Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Licenses SiRNA Selection Algorithm from Novartis

NEW YORK, Dec. 15 (GenomeWeb News) - Qiagen said today that it has licensed from Novartis a novel algorithm for the selection of siRNAs for RNA interference applications.

 

Under the terms of the deal, Qiagen made an undisclosed payment to Novartis for the worldwide use of the algorithm. Additional terms were not given.

 

Since acquiring Xeragon in 2002, Qiagen has introduced a number of RNAi products, including custom siRNA duplexes. Qiagen also signed a deal in August to provide Novartis with a genome-wide library of siRNAs for dr4ug discovery.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.